Chitosan and its derivatives as nanocarriers for siRNA delivery

被引:14
|
作者
Al-Qadi, S. [1 ]
Grenha, A. [2 ]
Remunan-Lopez, C. [1 ]
机构
[1] Univ Santiago de Compostela, Fac Pharm, Dept Pharm & Pharmaceut Technol, Nanobiofar Grp, Santiago De Compostela 15782, Spain
[2] Univ Algarve, IBB Inst Biotechnol & Bioengn, CBME Ctr Mol & Struct Biomed, Faro, Portugal
关键词
Chitosan; Chitosan derivatives; Formulation parameters; Gene silencing; Nanocarriers; siRNA delivery; SMALL INTERFERING RNA; TARGETED GENE DELIVERY; NUCLEIC-ACID DELIVERY; MOLECULAR-WEIGHT; IN-VITRO; DRUG-DELIVERY; ANTISENSE OLIGONUCLEOTIDES; ANTIINFLAMMATORY TREATMENT; NANOPARTICLE FORMULATION; INTRAVENOUS DELIVERY;
D O I
10.1016/S1773-2247(12)50003-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ability to specifically silence genes using siRNA has enormous potential for treating genetic diseases. However, siRNA instability and biodistribution issues still need to be overcome, and adequate delivery vehicles have proven indispensable in conveying siRNA to its target. Chitosan is a promising biopolymer for siRNA delivery, its interest stemming from its solely, biodegradability, mucoadhesivity, permeation enhancing effect and cationic charge, as well as amenability to undergo chemical modifications. Chitosan and its derivatives can be readily arranged into complexes or nanoparticles able to entrap and carry siRNA. Specific strategies have been adopted to improve chitosan-based vectors with regard to transfectability. However, further efforts cure required to verify their value and adapt them to enhance therapeutic output prior to clinical application. This review emphasizes the potential of chitosan and its derivatives to develop nanocarriers for siRNA delivery. The properties of chitosan that are significant for transfectability and the most relevant findings are assessed.
引用
收藏
页码:29 / 42
页数:14
相关论文
共 50 条
  • [21] Chitosan and Its Derivatives for Drug Delivery Perspective
    Sonia, T. A.
    Sharma, Chandra P.
    CHITOSAN FOR BIOMATERIALS I, 2011, 243 : 23 - 53
  • [22] Liposomal siRNA nanocarriers for cancer therapy
    Ozpolat, Bulent
    Sood, Anil K.
    Lopez-Berestein, Gabriel
    ADVANCED DRUG DELIVERY REVIEWS, 2014, 66 : 110 - 116
  • [23] Inhibition of osteoclastogenesis through siRNA delivery with tunable mesoporous bioactive nanocarriers
    Kim, Tae-Hyun
    Singh, Rajendra K.
    Kang, Min Si
    Kim, Joong-Huyn
    Kim, Hae-Won
    ACTA BIOMATERIALIA, 2016, 29 : 352 - 364
  • [24] Pegylated poly-L-arginine derivatives of chitosan for effective delivery of siRNA
    Noh, Sang Myoung
    Park, Myung Ok
    Shim, Gayong
    Han, Su Eun
    Lee, Han Young
    Huh, Jun Hyuk
    Kim, Myoung Suk
    Choi, Jin Joo
    Kim, Kwangmeyung
    Kwon, Ick Chan
    Kim, Jin-Seok
    Baek, Kwang-Hyun
    Oh, Yu-Kyoung
    JOURNAL OF CONTROLLED RELEASE, 2010, 145 (02) : 159 - 164
  • [25] Nanocarriers: a tool to overcome biological barriers in siRNA delivery
    Kumari, Avnesh
    Kumar, Vineet
    Yadav, Sudesh Kumar
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (10) : 1327 - 1339
  • [26] Nanocarriers for siRNA delivery to overcome cancer multidrug resistance
    MENG QingShuo
    YIN Qi
    LI YaPing
    Science Bulletin, 2013, (33) : 4021 - 4030
  • [27] Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery
    Lee, Dong Wook
    Yun, Kyoung-Soo
    Ban, Hong-Seok
    Choe, Wonchae
    Lee, Sang Kyung
    Lee, Kuen Yong
    JOURNAL OF CONTROLLED RELEASE, 2009, 139 (02) : 146 - 152
  • [28] Polymeric Nanoparticles of Chitosan Derivatives as DNA and siRNA Carriers
    Kim, Y. K.
    Jiang, H. L.
    Choi, Y. J.
    Park, I. K.
    Cho, M. H.
    Cho, C. S.
    CHITOSAN FOR BIOMATERIALS I, 2011, 243 : 1 - 21
  • [29] Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers
    Thakur, Ajit
    Fitzpatrick, Scott
    Zaman, Abeyat
    Kugathasan, Kapilan
    Muirhead, Ben
    Hortelano, Gonzalo
    Sheardown, Heather
    JOURNAL OF BIOLOGICAL ENGINEERING, 2012, 6 (01):
  • [30] Chitosan and its derivatives in mucosal drug and vaccine delivery
    van der Lubben, IM
    Verhoef, JC
    Borchard, G
    Junginger, HE
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (03) : 201 - 207